COST REIMBURSEMENT AGREEMENT Between PDS Biotechnology and THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONEdge Therapeutics, Inc. • January 25th, 2019 • Pharmaceutical preparations • Kentucky
THIS AGREEMENT, having an Effective Date of I November 2015, is made by and between PDS Biotechnology, a corporation having its principal place of business at 675 US Hwy I, North Brunswick, NJ 08902 (hereinafter referred to as "COMPANY"), and the UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, with offices and place of business at 109 Kinkead Hall, Lexington, KY 40506-0057 (hereinafter referenced to as "FOUNDATION") and
COST REIMBURSEMENT AGREEMENT between PDS Biotechnology and THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATIONEdge Therapeutics, Inc. • January 25th, 2019 • Pharmaceutical preparations • Kentucky
THIS AGREEMENT, having an Effective Date of 1 November 2015, is made by and between PDS Biotechnology, a corporation having its principal place of business at 675 US Hwy 1, North Brunswick, NJ 08902 (hereinafter referred to as “COMPANY”), and the UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, with offices and place of business at 109 Kinkead Hall, Lexington, KY 40506-0057 (hereinafter referenced to as “FOUNDATION”) and
Portions of this Exhibit have been redacted pursuant to a request for confidential treatment under Rule 406 of the Securities Act of 1933, as amended. Such redacted portions have been with “***” in this Exhibit. An unredacted copy of this document has...Chloride Enantiomer License Agreement • January 25th, 2019 • Edge Therapeutics, Inc. • Pharmaceutical preparations • New York
CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENTClinical Trial Collaboration and Supply Agreement • January 25th, 2019 • Edge Therapeutics, Inc. • Pharmaceutical preparations • New York
This CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT (this “Agreement”), made as of May 19, 2017 (the “Effective Date”), is by and between MSD International GmbH, having a place of business at Weystrasse 20,`6000 Luzern 6, Switzerland (“Merck”), and PDS Biotechnology Corporation having a place of business at Commercialization Center for Innovative Technologies, 675 US Highway One, North Brunswick, NJ 08902 USA (“PDS”). Merck, and PDS are each referred to herein individually as “Party” and collectively as “Parties”.
COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT FOR INTRAMURAL-PHS CLINICAL RESEARCHCooperative Research and Development Agreement • January 25th, 2019 • Edge Therapeutics, Inc. • Pharmaceutical preparations • District of Columbia
This Agreement is based on the model Cooperative Research and Development Agreement (“CRADA”) adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”).
